Skip to main content

Table 4 Univariate and multivariate cox regression models of tuberculosis in SpA

From: Risk of tuberculosis in patients with spondyloarthritis: data from a centralized electronic database in Hong Kong

  Univariate regression Multivariate logistic regression
Characteristic Hazard Ratio (95% CI) P value Hazard Ratio (95% CI) P value
Age (years) 0.93 (0.91–0.95) < 0.001 0.94 (0.91–0.96) < 0.001
Male sex 2.29 (1.02–5.15) 0.05 1.88 (0.79–4.50) 0.16
Smoking 1.74 (0.95–3.19) 0.07 1.19 (0.60–2.35) 0.62
Alcohol use 2.29 (1.06–4.94) 0.04 2.44 (1.03–5.80) 0.04
History of psoriasis 0.51 (0.21–1.20) 0.12   
History of IBD 1.43 (0.20–10.37) 0.73   
DM 0.72 (0.26–2.03) 0.54   
Past history of TB 6.88 (3.28–14.41) < 0.001 5.92 (2.52–13.94) < 0.001
CKD 0.89 (0.32–2.51) 0.83   
CLD 4.48 (2.07–9.72) < 0.001 3.81 (1.60–9.06) 0.002
Malignancy 2.07 (0.74–5.80) 0.17   
CHD 0.88 (0.31–2.47) 0.81   
Other immunosuppressive states 0.95 (0.13–6.89) 0.96   
History of CVA 1.46 (0.52–4.09) 0.48   
Glucocorticoid therapy > 6 months 2.21 (0.93–5.25) 0.03 2.60 (1.01–6.70) 0.05
Sulfasalazine 0.63 (0.34–1.16) 0.14   
Methotrexate 0.57 (0.27–1.19) 0.13   
Lefluonomide 0.05 (0.00–13.72) 0.29   
Infliximab 5.08 (2.49–10.34) < 0.001 3.94 (1.82–8.53) < 0.001
Etanercept 0.57 (0.14–2.36) 0.44   
Adalimumab 1.83 (0.72–4.67) 0.21   
Certolizumab 0.05 (0.00–32,169) 0.66   
Golimumab 0.05 (0.00–13.94) 0.29   
Secukinumab 0.05 (0.00–282.43) 0.49   
Ustekinumab 0.05 (0.00–657,547) 0.72   
  1. SpA Spondyloarthritis; CI Confidence interval; IBD Inflammatory bowel disease; DM Diabetes mellitus; TB Tuberculosis; CKD Chronic kidney disease; CLD Chronic lung disease; CHD Chronic heart disease; CVA Cerebrovascular accident